| ABBV |
Report |
Total net revenue (Q2 2026) |
BEAT |
pred ~$17.0B vs. cons $16.81B |
MEDIUM |
| ABBV |
Report |
Skyrizi net revenue (Q2 2026) |
BEAT |
pred ~$5.65B vs. cons $5.52B |
MEDIUM |
| ABBV |
Report |
Rinvoq net revenue (Q2 2026) |
BEAT |
pred ~$2.55B vs. cons $2.49B |
MEDIUM |
| ABBV |
Guide |
FY2026 net revenue guide |
BETTER |
guide ~$67.6B vs. cons ~$67.4B (FY2026) |
MEDIUM |
| ABBV |
Guide |
FY2026 adjusted EPS guide (all-in, incl. IPR&D) |
LOWER |
guide ~$14.05 (raise $13.95-14.15) vs. cons $14.18 (FY2026) |
MEDIUM |
| ABBV |
Guide |
FY2026 Skyrizi+Rinvoq combined guide |
BETTER |
guide ~$32.2B vs. cons ~$31.9B (FY2026) |
MEDIUM |
| ABBV |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| ABBV |
Return |
5-day cumulative residual |
+0.5% (FADE) |
Clean underlying revenue beat + a modest FY sales raise (Skyrizi/Rinvoq momentum) should spark an initial pop, but the stock is extended (~30% off April lows, ~2% below all-time highs, priced for beat-and-raise). The all-in FY adj EPS framework (~$14.05 mid) does not clear the Street's $14.18 because the $0.17 Q2 IPR&D drag and low-single-digit H2 Skyrizi price erosion cap out-period upside; with EPS revisions flat-to-lower and aesthetics still soft, the day-1 gain partially fades over the week as low-beta (~0.3) defensive positioning limits both upside and downside. |
LOW |